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Abstract 
 
Objectives 
The present study aims to evaluate existing policy and practice relating to the use of 
pharmacological treatments with patients suffering from paraphilic disorders who are at risk 
of committing further sexual offences.  
Methods 
A systematic literature search was conducted to document current legal policies across 26 
different countries. Additionally, a questionnaire assessing the practice of pharmacological 
treatment was sent to practitioners involved in the treatment of patients with paraphilic 
disorders.  
Results 
Legal policies concerning the preconditions of using pharmacological treatments differ 
considerably between countries and for most jurisdictions do not exist. Drawing on the 
responses of 178 practitioners, pharmacological agents are a useful addition to 
psychotherapeutic interventions, especially with those patients classified as medium to high 
risk for sexually violent behaviours. It would appear that most patients are medically 
examined, are informed of the risks and possible side effects before treatment commences and 
are also obliged to sign a consent form.  
Conclusions 
Although pharmacological agents can be seen as an intrusion into a patients’ sexual self-
determination, results indicate that ethical and clinical standards are being met in the majority 
of cases. However, further promotion of current WFSBP-treatment guidelines would help to 
standardize practice across North American and European countries. 
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Introduction 
The presence of paraphilic disorders in individuals has been found to be a major risk 
factor in sexual offending, with at least one paraphilic disorder being found in approximately 
50% of sexual offender samples (Eher et al. 2010; Hanson & Morton-Bourgon 2005). 
Recognizing the close link between these disorders and sexual offending, the World 
Federation of Societies of Biological Psychiatry (WFSBP) treatment guidelines set out a 
hierarchy of drugs to be used with those who present with paraphilic fantasies and impulses 
and are deemed risky in terms of criminal behaviour. According to the guidelines, clinicians 
should first use selective-serotonin-reuptake-inhibitors (SSRIs), followed by steroidal 
antiandrogens (cyproterone acetate (CPA) or medroxyprogesterone acetate (MPA)) and 
finally gonadotropin-releasing-hormone-agonists (GnRH-agonists) (Thibaut et al. 2010). On 
the basis that both steroidal antiandrogens and GnRH-agonists lead to a considerable decrease 
in serum testosterone levels they are referred to as androgen deprivation therapy (ADT). 
Factors which clinicians usually take into consideration when making the decision whether or 
not ADT should be used include a history of previous treatment failures and sexual violations 
while either in detention or under community supervision (Turner et al. 2014).  
Although pharmacological agents are frequently used in the treatment of paraphilic 
disorders (Basdekis-Jozsa et al. 2013; McGrath et al. 2010), effectiveness studies are limited 
(e.g. Khan et al. 2015; Koo et al. 2013; Kraus et al. 2006; Maletzky et al. 2006). Moreover, 
and especially in relation to ADT, there are a variety of negative side effects including weight 
gain, gynaecomastia, reduced testicle volume, hot flushes, reduced bone mineral density, and 
hepatotoxicity. These and other concerns, relating to issues such as consent, have provoked 
ethical questions concerning their use (Basdekis-Jozsa et al. 2013; Cherrier et al. 2010; 
Gooren 2011; Harrison 2008; Khan & Mashru 2016). 
 Due to such concerns, it would be desirable to first harmonize and then standardize the 
management and treatment of those paraphilic patients who present a risk of sexually violent 
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behaviours, which will ensure that all ethical and medical standards are being met. For 
example, this should include unity in decisions relating to practice including: 1) Who is 
suitable for pharmacological treatment, 2) Who decides when pharmacological agents are to 
be used , 3) Whether treatment is provided on a voluntary or mandatory basis, and  4) In 
which institutions paraphilic patients should be treated. This task of harmonising and 
standardising practice is important, not least because of increasing internationalization and 
globalization. It is now not uncommon for paraphilic patients who have committed a sexual 
offence to be convicted, incarcerated, and receive treatment outside of their home country or 
to be transferred back to their country of origin following release from prison or comparable 
institution (Salize et al. 2005). Furthermore, with a rise in child trafficking for sexual 
purposes, especially throughout European and North American countries, the synchronization 
of practice is essential (Koops et al. 2017) and should be based on sound empirical data 
(Salize et al. 2005).   
Given this, the present study looked to evaluate the current practice of 
pharmacotherapy with patients suffering from paraphilic disorders in three different 
geographical regions: North America, Western Europe and Eastern Europe. These areas were 
chosen as they share a broad historical and legal background. The research involved 
collecting and assessing the opinions of practitioners engaged in administering 
pharmacological treatment to individuals with a paraphilic disorder. Based on current research 
it is reasonable to conclude that most paraphilic patients treated with pharmacological agents 
have been convicted of a sexual offence. To enable a precise analysis and interpretation of 
practitioners’ views it was therefore important to assess the legislative basis for this treatment. 
This approach enabled us to analyse and discuss the results in light of differing legal systems 
and the recommendations provided by the WFSBP guidelines (Thibaut et al. 2010). 
 
Materials and Methods 
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Legislation and policy 
 In order to obtain information on the legislative basis for treating paraphilic patients at 
risk of committing sexual offences with pharmacotherapy, a systematic literature search was 
conducted in the included countries looking for relevant legal frameworks or policy 
documents. This was achieved using PubMed, Google, and Google Scholar and the search 
terms: “sexual offender treatment,” “antiandrogens,” “chemical castration,” “Androgen 
Deprivation Therapy” AND “law,” “legal,” “directive,” AND the single North American and 
European countries. Only publications in German and English were reviewed. To ensure that 
information on legal policies was up-to-date, the search was restricted to data published 
between January 2000 and May 2017. Where no reliable information could be found for a 
country (for example where only newspaper reports but no scientific publications were 
identified) relevant experts from these selected countries were directly contacted and 
information obtained. 
 
Expert opinion on the current clinical practice 
Participants  
Participants of the questionnaire were identified using Google and the terms: “forensic 
psychiatry,” “forensic psychology,” “forensic outpatient clinic,” “forensic hospital,” 
“psychiatry,” “prison,” AND the single countries of North America and Europe. The search 
was conducted in English. The first 100 results of every search were analysed looking for 
individuals who were potentially involved in the treatment of sexual offenders. When email 
addresses could be identified, individuals were contacted and invited to participate in the 
study. The study invitation was also sent to members of the International Association for the 
Treatment of Sexual Offenders, the American Association for the Treatment of Sexual 
Abusers, the European Association of Psychology and Law, the European Psychiatric 
! 6 
Association, the World Psychiatric Association, and the World Health Organization Health in 
Prisons Programme.  
In total 729 people responded to the invitation and submitted partial or fully completed 
questionnaires. For meaningful analyses, however, only those participants who completed the 
entire questionnaire were included. This reduced the sample size to 178 individuals (24.4% of 
the initial sample). The three regions (North America, Western Europe and Eastern Europe) 
yielded participants from 26 different countries: the United States of America (US), Canada, 
Austria, Belgium, Denmark, England, Finland, France, Germany, Greece, Ireland, Italy, The 
Netherlands, Portugal, Spain, Sweden, Switzerland, Croatia, Czech Republic, Estonia, 
Hungary, Latvia, Poland, Russia, Slovakia, and Slovenia. Table 1 presents an overview of the 
socio-demographic information of these participants.  
 
*** Please insert table 1 about here *** 
 
Questionnaire and data acquisition 
 Data acquisition was achieved through a self-constructed questionnaire. All 
participants were informed of the study’s objectives, were assured of confidentiality, and 
notified of ethical approval. This was given by the ethical review board of the Chamber of 
Psychotherapists, Hamburg, Germany. The questionnaire was programmed using Questback 
EFS Survey 10.2 (Questback GmbH, Cologne, Germany). All raw data were saved on 
Questback servers, which met all national requirements concerning data protection and safety 
according to the German Federal Office of Information Security 
(http://www.questback.com/de/datenschutz-datensicherheit.html). 
   
Statistical Analyses 
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All statistical analyses were conducted using IBM SPSS Statistics for Macintosh, 
Version 22.0 (Amonk, NY, USA). Answers were compared utilizing ANOVAs for 
continuous variables and chi-square tests for categorical variables. Furthermore, results were 
also compared between those countries (or US states) that have legal statutes allowing for 
mandatory ADT and those that provide ADT on a voluntary basis. Only those participants 
who had actually prescribed pharmacological agents for treating paraphilic disorders were 
included in this last step of the analyses.  
 
Results 
Legislation and policy 
In the US, SSRIs, MPA, and GnRH-agonists are commonly used in the treatment of 
paraphilic disorders (McGrath et al. 2010). This is the case, even though their use for this 
purpose is off label, i.e. it deviates from Federal Drug Administration approval. In Canada 
and Europe SSRIs, CPA and GnRH-agonists are normally used (Holoyda & Kellaher 2016). 
European authorities approved the use of CPA in the treatment of paraphilic disorders in 1973 
and GnRH-agonists in 2007. Triptorelin is currently the only GnRH-agonist officially 
approved for use with severe paraphilic disorders (Thibaut et al. 2010), although other GnRH-
agonists (goserelin, buserelin, and leuprolide) are commonly used as well. 
Historically, eight US states (California, Florida, Iowa, Louisiana, Oregon, Montana, 
Wisconsin, Georgia), had legal statues allowing for the use of ADT in paraphilic patients who 
had committed a sexual offence (Douglas et al. 2013); although actual implementation in each 
state varied. More recently, this legislation has been repealed in both Georgia and Oregon 
(Vaillancourt 2012). ADT is currently provided on a voluntary basis in Montana and 
Wisconsin and available on a mandatory basis (where a paraphilic patient has been convicted 
of at least two sexual offences) in California, Florida, Iowa, and Louisiana (del Busto & 
Harlow 2011; Scott & Holmberg 2003). In Florida ADT can be used with all paraphilic 
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patients who have committed a sexual offence, while in the remaining five states it can only 
be administered to those patients who have sexually abused children (age of the victim: < 
13years in California, Iowa, Louisiana, Wisconsin; < 16 years in Montana) (Scott & 
Holmberg 2003). Interestingly, in Texas, while there is legal provision for surgical castration, 
there is no legal basis for the use of ADT (Douglas et al. 2013). Despite a lack of legal 
provisions, ADT and/or other pharmacological agents are used in most other states of the US 
(McGrath et al. 2010). Of those states that do have a legislative basis, none require additional 
psychotherapy nor have specifications concerning the medical monitoring of side effects 
during pharmacological treatment (Scott & Holmberg 2003; Vaillancourt 2012).  
In Europe, almost all countries that permit the use of ADTs do so on a voluntary basis. 
In some of these countries, for example Belgium, Denmark, Estonia, and Sweden, psychiatric 
treatment, including pharmacological treatment, can be implemented as a formal condition of 
parole (Douglas et al. 2013; Koch-Arzberger et al. 2011; Kristensen et al. 2011). In Denmark, 
for example, individuals with a paraphilic disorder who were convicted of a sexual offence 
and who pleaded guilty can voluntarily choose to be treated with ADT (Aagaard 2014). ADT 
can be implemented as a precondition of parole or probation or as a condition of release from 
an indefinite sentence (Aagaard 2014). In all cases the Danish Legal Medical Council has to 
approve the treatment, once extensive mental and physical examinations have been completed, 
although the final decision about an individual’s suitability is made by the Prison and 
Probation Service (Aagaard 2014).  
 In other European countries there is no legal connection between ADT treatment and 
parole. German law states that people with a severe sexual preference disorder can be treated 
with ADT on a voluntary basis if they have been extensively informed about the risks and 
negative side effects of the treatment and about all other treatment options. This also applies 
to adolescents, as long as their legal guardian has given informed consent (Law on voluntary 
castration and other treatment methods; [Gesetz über die freiwillige Kastration und andere 
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Behandlungsmethoden; KastrG]; inception on 15th Feb. 1970; last change: 10th Nov. 2016). In 
Switzerland Article 434 of the Civil Code allows for the mandatory use of medications 
including ADT (although not explicitly mentioned) if the patient is at risk of causing harm to 
himself or to others, suggesting that theoretically ADT could be applied to those individuals 
who display a high risk for future criminal behaviours. Despite such legislation, however, in 
practice ADT is only provided for on a voluntary basis and does not have any association with 
early release or parole (Tileman 2016). Moldova, Estonia, Canada, Hungary, Austria, France, 
Norway, the Netherlands, Finland, Iceland, Italy, Latvia, Spain, the Czech Republic, and the 
United Kingdom (UK) also permit the use of ADT on a voluntary basis. To our knowledge 
there is no link between the undertaking of treatment and early release or parole in these 
countries (Akbaba 2015; Directorate General For Internal Policies 2013; Koshevaliska 2014; 
McAlinden 2012). Moreover, although pharmacological treatments and, especially, ADT are 
used in these countries, there is very little in terms of legal regulations. No such laws exist, for 
example, in the UK. 
In 2010, Poland became the first European country to introduce court-ordered 
mandatory pharmacological treatment for anyone found guilty of having sexually abused a 
child under the age of 15 years (McAlinden 2012). Macedonia has also recently enacted 
similar legislation (Koshevaliska 2014). Here, first time sexual offenders can choose to be 
treated with ADT on a voluntary basis in order to reduce the prison sentence (Ratkoceri 2017). 
Furthermore, all individuals who have been convicted of a second sexual offence can be 
treated on a mandatory basis as long as the court believes that the individual is at risk of 
committing another sexual offence (Koshevaliska 2014; Ratkoceri 2017). As far as we could 
determine there seems to be no specification that the patient has to be diagnosed with a 
paraphilic disorder in order to fall into this category. The Russian Penal Code states that a 
court can impose “compulsory measures of a medical nature” (Article 97) on persons aged 18 
or older who have committed a sexual offence against a child (classed as under 14 years of 
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age) and who suffer from a sexual preference disorder (Tileman 2016). The offender also has 
to be at risk of committing further damage or danger to himself or others (Tileman 2016). In 
2012, Moldova also introduced the use of mandatory ADT for anyone convicted of having 
sexually abused a child aged 15 years or under (Tileman 2016), however, this was repealed in 
2013 because of human rights concerns.  
As far as we have been able to determine, Greece and Portugal are the only European 
countries in which paraphilic patients who have committed a sexual offence are not treated 
with ADT (2017 personal email communication between O. Giotakos and the first author for 
Greece, and personal email communication between R. Barroso and the first author for 
Portugal, both unreferenced). We were unable to find any reliable information for Croatia, 
Slovakia, or Slovenia 1.  
 
Expert opinion on current clinical practice 
Where multiple answers were allowed, forensic-psychiatric hospitals (North America: 
88.4%, Western Europe: 85.0%, Eastern Europe: 65.7%) were cited as the most common 
institutions in which paraphilic patients convicted for a sexual offence were treated using 
pharmacological agents. This was followed by outpatient care settings (North America: 
83.7%, Western Europe: 72.0%, Eastern Europe: 51.4%), and prisons (North America: 44.2%, 
Western Europe: 53.0%, Eastern Europe: 31.4%) (Forensic-psychiatric hospitals = outpatient 
care settings > prisons for all three regions)2. Asking participants which pharmacological 
agents were used most frequently in treating paraphilic disorders in their country (only one 
answer was allowed), participants from North American and Western European countries 
indicated that SSRIs were used most frequently (North America: 65.1%; Western Europe: 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!1 None of the contacted experts replied to our request on providing us with information about the legal practice 
concerning the use of ADT in the aforementioned countries. 
2 Significant differences refer to p < .05 
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41.0%), followed by steroidal antiandrogens (North America: 14.0%; Western Europe: 
17.0%), GnRH-agonists (North America: 7.0%; Western  
Europe: 13.0%), and antipsychotics (North America: 2.3%; Western Europe: 10.0%) (North 
America: SSRIs > antiandrogens = GnRH-agonists > antipsychotics; Western Europe: SSRIs 
> antiandrogens = GnRH-agonists = antipsychotics)2. Participants from Eastern European 
countries reported that steroidal antiandrogens (31.4%) and antipsychotics (28.6%) were used 
more often than SSRIs (5.7%) and GnRH-agonists (2.9%) (Eastern Europe: Antiandrogens = 
antipsychotics > SSRIs = GnRH agonists)2. 
An overview of the participants’ opinions as to whether pharmacological agents 
should ever be used in the treatment of sexually deviant behaviours in individuals convicted 
of a sexual offence is presented in Table 2. This also shows what others factors have to be 
certified before treatment can begin, for example, whether patients are informed about the 
possible risks and side effects, whether patients have to give written informed consent, and 
whether patients are notified that their consent can be revoked. Perhaps unsurprisingly, the 
more high-risk a patient is in terms of showing future sexually violent behaviours, the more 
appropriate practitioners thought the use of ADT treatment was. This view was shared by 
most participants across the three regions and is presented in Table 3. 
 
*** Please insert table 2 and 3 about here *** 
 
In order to compare the opinion of participants from countries with different legal 
provisions the sample was divided into participants coming from those countries or US states 
which provide ADT on a voluntary basis (U.K., Denmark, Netherlands, Czech Republic, 
Spain, Canada, Germany, Belgium, Austria, France, Switzerland, Sweden, Finland, Estonia, 
Italy, Latvia, Portugal, Ireland, U.S. state except California, Florida, Iowa, Louisiana; n = 57) 
and those that impose it mandatorily (California, Florida, Iowa, Louisiana, Poland and Russia; 
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n = 12 participants). This is presented in Table 4. Due to incomplete information concerning 
the legal basis of ADT in Croatia, Slovakia, and Slovenia, participants from these countries 
were excluded from this analysis.  
 
*** Please insert table 4 about here *** 
 
Discussion 
 Although pharmacological agents are used in almost all North American and European 
countries for the treatment of those paraphilic patients who are at risk of committing further 
sexual offences, most countries do not have official laws regulating their use. Moreover, even 
where legal statutes do exist, these vary considerably and therefore do not present us with a 
unified or standardised approach. Most jurisdictions do not specify that pharmacological 
treatment should be restricted to patients with paraphilic disorders and thus it appears that 
such treatment can be given to any individual at risk of committing further sexual offences; 
this is especially the case in those countries which have mandatory treatment options. Where 
there is no therapeutic need, the use of pharmacological treatment here can only be viewed as 
punitive, raising medical ethics questions. Moreover, previous research has indicated that 
even where legal policies do exist they are not necessarily followed in practice. For example, 
although there is no official link between pharmacotherapy and early release in Germany, 
Briken and colleagues have found that those patients with a paraphilic disorder currently 
placed in prison or similar institutions who decide to be treated with ADT are more likely to 
be considered for home leave than those who are not treated (Briken et al. 2009).  
Comparing the treatment numbers from our study with earlier studies it can be 
concluded that the percentage of paraphilic patients being treated with ADT has remained 
quite stable across the last two decades. Around 10% to 15% of patients who have committed 
a sexual offence are treated with ADT with the aim being to reduce paraphilic fantasies and 
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urges (Cosyns 1999; Czerny et al. 2002; Turner et al. 2013). This indicates that although 
current meta-analyses are sceptical about the actual effectiveness of pharmacological agents 
(Khan et al. 2015; Langström et al. 2013; Schmucker & Lösel 2015), clinical experience 
suggests that for some paraphilic patients medication is a useful addition to psychotherapeutic 
interventions and, as such, its use is being recommended by both clinicians and the WFSBP 
guidelines (Thibaut et al. 2010). Recent research suggests that the agents used in the treatment 
of paraphilic disorders, seem to be helpful in the treatment of men with a hypersexual disorder 
as well (Kaplan & Krueger 2010; Wainberg et al. 2006; Safarinejad 2009). For example, 
Winder et al. (2017) reported on a sample of 127 adult male prisoners serving sentences for 
sexual offences in a UK prison who were treated with either SSRIs or steroidal antiandrogens 
for hypersexual disorder. Both agents led to a significant decrease in 1) the number of days on 
which participants masturbated to orgasm, 2) the time spent thinking about sex, and 3) the 
strength of sexual urges. Initial effects were noticed within one month and increased over a 
period of six months (Winder et al. 2017). This treatment approach could be due to 
similarities of paraphilic and hypersexual disorders, because both types of disorders 
frequently involve sexual behaviour that cannot be controlled by the patient (Kaplan & 
Krueger 2010; Krueger & Kaplan 2001). However, the relationship between hypersexual 
behaviours and sexual offending is less clear compared to the association between paraphilic 
disorders and sexual offending and only few individuals presenting with hypersexual 
behaviours sexually offend (Klein et al. 2015; Turner et al. 2014). 
Although the current state of research suggests that pharmacological agents are useful 
in the reduction of general sexual drive, their use is accompanied by many ethical concerns. 
This is especially the case for ADT, where it has been argued that it restricts a patient’s ability 
to have a self-determined sexual life and consequently may violate basic human rights 
(Basdekis-Jozsa et al. 2013). Depending on the specific dosage and application method ADT 
can lead to a complete decline of sexual fantasies, urges and behaviours also including non-
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paraphilic sexual behaviours. This suggests that ADT should be reserved for those patients 
with the most intense paraphilic disorders, as it would be ethically questionable to prevent the 
possibility of having a functional sex life in patients with less severe paraphilic disorders.  
In order to ensure that medical and ethical standards are met and that the harmful 
nature of the treatment is kept to a minimum, all pharmacological treatments must be carried 
out on a completely voluntary basis and should be restricted to patients with a paraphilic 
disorder. To guarantee voluntary treatment the WFSBP guidelines recommend extensively 
informing all patients about potential risks and side effects, in addition to perceived benefits 
before asking for written consent. It is only through the provision of adequate information that 
consent can be informed consent. This is important bearing in mind that current laws do not 
specify such requirements. Overall, our study reports that most, but not all, treatment 
providers meet these preconditions. However, it has to be noted that in those countries where 
taking medication is a precondition of early release or parole it is questionable whether 
voluntary and informed consent can ever be achieved. Even where there is no official link to 
early release or parole it cannot be ruled out that a paraphilic patient who is placed in prison 
or a comparable institution is only consenting to treatment because he believes that taking part 
in such a program will be viewed positively by the supervisory authorities (Harrison 2008). In 
this context, one surprising finding is that even from those countries or US states who 
legislate for mandatory treatment, the majority of participants nevertheless stated that patients 
still had to give their written informed consent before pharmacological treatment would 
commence. This finding could show that treatment providers do not agree with this mandate 
and thus ask for their patients’ written informed consent despite not actually needing it. 
Moreover, mandatory treatment can only be applied to certain patients fulfilling specific 
criteria and only a minority of individuals are likely to fulfil these criteria. It could therefore 
be the case that these practitioners are actually treating many more paraphilic patients 
voluntarily than they are on a mandatory basis. However, even if the number of patients who 
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are being treated mandatorily is very small, ethically the most appropriate approach would be 
to provide voluntary treatment for all patients with a paraphilic disorder and to decouple 
decisions on parole from those involving pharmacological treatment. 
Furthermore, in line with WFSBP guidelines, the vast majority of participants 
indicated that psychotherapy is provided in conjunction with pharmacological treatment. This 
is especially noteworthy, considering that where legal statutes exist, they do not explicitly 
require this additional psychotherapy. Taken together, these findings suggest that in many 
cases clinical practice seems to be more advanced and more ethically sound than the 
legislation that governs it. 
 The findings of the present study are limited because they only provide a subjective 
view about the practice of pharmacological sexual offender therapy and do not necessarily 
represent the actual clinical practice in the included countries and states. Representativeness 
of the findings is also limited due to the high dropout rate and the number of participants from 
some single countries being quite small. Although reliable evidence was found concerning the 
legal policies for most countries, we did not examine actual legislation. Such an approach 
would have been beyond the scope of the present study. However, this would be a worthwhile 
goal for future studies. Furthermore, any connection between taking medication and early 
release should be urgently addressed as such a link threatens the validity of informed consent 
for individuals treated under these conditions. Future research should also compare actual 
practice and policy concerning the use of pharmacological treatment for paraphilic disorders 
in adolescents who are at risk of sexual offending. This should be done on a pan-country basis 
and assess this in light of recently published WFSBP treatment-guidelines on adolescents 
(Thibaut et al. 2016).  
 Differences in policy and legislation exist in various countries resulting in uncertainty 
for some treatment providers, as is shown by the discrepancies between the participants’ 
answers and the actual legal policies of the countries and states in which they practice. 
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Furthermore, legal policies in some countries are arguably ethically and medically unsound. 
Much work therefore remains in terms of harmonising and standardizing practice, especially 
in the case of individuals who have been in contact with the legal system. Although current 
guidelines help to define the preconditions and circumstances of treatment, the actual decision 
about whether or not a paraphilic patient is suitable for pharmacological treatment should 
always be made on a case by case basis. Furthermore, because pharmacological treatment and 
especially ADT can limit a patients’ freedom and human rights, it is extremely important that 
ethical and clinical standards, some of which are stated in the WFSBP guidelines, be followed 
and that further surveys and research concerning pharmacological treatment be conducted. 
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Table 1 
Socio-dem
ographic inform
ation of the study participants depending on geographical region and previous experiences w
ith prescribing pharm
acological agents 
Participants divided according to the geographical region 
 
 
N
orth A
m
erica (n = 43, 24.2%
) 
W
estern Europe (n = 100, 56.2%
) 
Eastern Europe (n = 35, 19.7%
) 
 
n (%
) / M
 (SD
; range) 
n (%
) / M
 (SD
; range) 
n (%
) / M
 (SD
; range) 
A
ge 
52.42 (SD
 = 11.97; 31 – 78 years) 
44.23 (SD
 = 10.07; 25 – 65 years) 
49.51 (SD
 = 13.89; 27 – 82 years) 
G
ender 
25 m
ale (58.1%
) 
18 fem
ale (41.9%
) 
59 m
ale (59.0%
) 
41 fem
ale (41.0%
) 
24 m
ale (68.6%
) 
11 fem
ale (31.4%
) 
Profession 
• 
Physician 
• 
Psychologist 
• 
O
ther 
 
14 (32.6%
) 
27 (62.8%
) 
2 (4.7%
) 
 
53 (53.0%
) 
42 (42.0%
) 
5 (5.0%
) 
 
17 (48.6%
) 
14 (40.0%
) 
4 (11.4%
) 
Experience in treating paraphilic 
patients 
42 (97.7%
) 
84 (84.0%
) 
31 (88.6%
) 
Y
ears of experience in treating 
paraphilic patients 
16.85 (SD
 = 8.93; 2 – 45 years) 
11.38 (SD
 = 7.88; 1 – 43 years) 
13.47 (SD
 = 9.87; 1 – 37 years) 
Ever used pharm
acological agents  
• 
SSR
Is 
• 
A
ntipsychotics 
• 
C
PA
/M
PA
 
• 
G
nR
H
 agonists 
23 (53.5%
) 
20 (87.0%
) 
9 (39.1%
) 
17 (73.9%
) 
11 (47.8%
) 
43 (43.0%
) 
38 (88.4%
) 
16 (37.2%
) 
28 (65.1%
) 
22 (51.2%
) 
14 (40.0%
) 
9 (64.3%
) 
9 (64.3%
) 
14 (100%
) 
9 (64.2%
) 
Y
ears of using pharm
acological 
agents  
14.75 (SD
 = 7.91; 3 – 30 years) 
8.52 (SD
 = 6.03; 2 – 25 years) 
13.86 (SD
 = 11.79; 1 – 37 years) 
Table 2  
 C
linical and practical fram
ew
ork concerning the pharm
acological treatm
ent of paraphilic patients w
ho have com
m
itted or are at risk for com
m
itting a sexual offence depending 
on the geographical region. 
 
N
orth A
m
erica 
(n = 43) 
W
estern E
urope 
(n = 100) 
E
astern E
urope 
(n = 35) 
 
 
V
ariables influencing clinical and practical fram
ew
ork
1 
n (%
) 2 /M
 (SD
) 
n (%
) 2 /M
 (SD
) 
n (%
) 2 /M
 (SD
) 
χ
2 / F 
p 
Should paraphilic patients ever be treated w
ith A
D
T?
 
35 (81.4%
) 
69 (69.0%
) 
22 (62.9%
) 
4.78 
.31 
Should paraphilic patients ever be treated w
ith other m
edications (e.g. SSR
Is, 
antipsychotics)?
 
38 (88.4%
) 
76 (76.0%
) 
23 (65.7%
) 
7.23 
.12 
H
ow
 m
any paraphilic patients are treated w
ith m
edications for sexual deviance? 
14.6%
 (SD
 = 10.8) 
12.6%
 (SD
 = 15.6) 
28.4%
 (SD
 = 35.7) 
2.98 
.06 
H
ow
 m
any paraphilic patients are treated w
ith A
D
T for sexual deviance? 
5.8%
 (SD
 = 3.9)a 
6.1%
 (SD
 = 10.9)a 
19.4%
 (SD
 = 29.5)b 
3.32 
.04 
Is psychotherapy provided alongside pharm
acological treatm
ent? 
32 (74.4%
) 
80 (80.0%
) 
30 (85.7%
) 
1.53 
.47 
A
re paraphilic patients m
edically exam
ined before treatm
ent? 
36 (83.7%
) 
95 (95.0%
) 
33 (94.3%
) 
5.56 
.06 
A
re paraphilic patients inform
ed about risks and side effects before 
pharm
acological treatm
ent is com
m
enced? 
42 (97.7%
)a 
97 (97.0%
)a 
29 (82.9%
)b 
10.94 
.01 
D
o paraphilic patients have to give w
ritten inform
ed consent before 
pharm
acological treatm
ent is com
m
enced? 
33 (76.7%
) 
79 (79.0%
) 
26 (74.3%
) 
.35 
.84 
C
an inform
ed consent be revoked after treatm
ent has com
m
enced?
3 
32 (97.0%
) 
76 (96.2%
) 
23 (88.5%
) 
2.81 
.25 
W
ould a lesser prison sentence or early parole be offered to a paraphilic patient in 
prison or com
parable institution if he agrees to pharm
acological treatm
ent? 
11 (25.6%
) 
39 (39.0%
) 
17 (48.6%
) 
4.52 
.10 
O
nce treatm
ent has started is the patient’s suitability subject to review
? 
41 (95.3%
) 
92 (92.0%
) 
32 (91.4%
) 
.60 
.74 
H
ow
 often is suitability assessed once treatm
ent has started? (m
onth) 
5.0 (SD
 = 4.7) 
6.8 (SD
 = 5.1) 
5.0 (SD
 = 1.6) 
.85 
.44 
W
ould the patient’s partner or w
ife be involved in the decision about 
pharm
acological treatm
ent? 
12 (27.9%
)a 
55 (55.0%
)b 
21 (60.0%
)b 
10.77 
.01 
N
ote. 1 Paraphilic patients refer to those w
ho have com
m
itted or are at risk of com
m
itting a sexual offence. 2 The num
bers refer to the am
ount of participants w
ho answ
ered yes to 
the according question. 3 O
nly participants w
ho answ
ered yes to the question if sexual offenders have to give w
ritten inform
ed consent before pharm
acological treatm
ent w
ere 
able to answ
er this question. V
alues w
ith different subscripts differ significantly p < .05. A
D
T = androgen deprivation therapy
Table 3 
Most appropriate treatment option depending on the paraphilic patient’s risk for future sexually violent 
behaviours. 
 Risk category 
 low medium high 
Treatment option n (%) n (%) n (%) 
Whole sample (n = 178)    
Psychotherapy 155 (87.1%) 139 (78.1%) 121 (68.0%) 
SSRIs 69 (38.8%) 83 (46.6%) 69 (38.8%) 
MPA/CPA 26 (14.6%) 87 (48.9%) 119 (66.9%) 
GnRH – agonists 14 (7.9%) 45 (25.3%) 104 (58.4%) 
Surgical castration 5 (2.8%) 10 (5.6%) 38 (21.3%) 
North America (n = 43)    
Psychotherapy 41 (95.3%) 40 (93.0%) 37 (86.0%) 
SSRIs 13 (30.2%) 25 (58.1%) 23 (53.5%) 
MPA/CPA 5 (11.6%) 19 (44.2%) 40 (93.0%) 
GnRH – agonists 3 (7.0%) 8 (18.6%) 26 (60.5%) 
Surgical castration 0 0 7 (16.3%) 
Western Europe (n = 100)    
Psychotherapy 87 (87.0%) 71 (71.0%) 59 (59.0%) 
SSRIs 44 (44.0%) 55 (55.0%) 35 (35.0%) 
MPA/CPA 9 (9.0%) 48 (48.0%) 62 (62.0%) 
GnRH – agonists 5 (5.0%) 28 (28.0%) 64 (64.0%) 
Surgical castration 2 (2.0%) 6 (6.0%) 17 (17.0%) 
Eastern Europe (n = 35)    
Psychotherapy 27 (77.1%) 28 (80.0%) 25 (71.4%) 
SSRIs 12 (34.3%) 3 (8.6%) 11 (31.4%) 
MPA/CPA 12 (34.3%) 20 (57.1%) 17 (48.6%) 
GnRH – agonists 6 (17.1%) 9 (25.7%) 14 (40.0%) 
Surgical castration 3 (8.6%) 4 (11.4%) 14 (40.0%) 
Table 4  
 C
linical and practical fram
ew
ork concerning the pharm
acological treatm
ent of paraphilic patients w
ho have com
m
itted or are at risk for com
m
itting a sexual offence depending 
on the legal background.  
  N
ote. 1 Paraphilic patients refer to those w
ho have com
m
itted or are at risk of com
m
itting a sexual offence. 2 The num
bers refer to the am
ount of participants w
ho answ
ered yes to 
the according question. 3 O
nly participants w
ho answ
ered yes to the question if sexual offenders have to give w
ritten inform
ed consent before pharm
acological treatm
ent w
ere 
able to answ
er this question. A
D
T = androgen deprivation therapy.!
 
M
andatory A
D
T
 
(n = 12) 
V
oluntary A
D
T
 
(n = 57) 
 
 
V
ariables influencing clinical and practical fram
ew
ork
1 
n (%
) 2 /M
 (SD
) 
n (%
) 2 /M
 (SD
) 
χ
2 / T 
p 
Should paraphilic patients ever be treated w
ith A
D
T?
 
9 (75%
) 
43 (75.4%
) 
.11 
.74 
Should paraphilic patients ever be treated w
ith other m
edications (e.g. SSR
Is, 
antipsychotics)?
 
11 (91.6%
) 
47 (82.5%
) 
.13 
.72 
H
ow
 m
any paraphilic patients are treated w
ith m
edications for sexual deviance? 
27.8%
 (SD
 = 16.45)  
12.8%
 (SD
 = 16.27) 
2.90 
.01 
H
ow
 m
any paraphilic patients are treated w
ith A
D
T for sexual deviance? 
20.3%
 (SD
 = 12.33) 
10.3%
 (SD
 = 14.22) 
2.26 
.03 
Is psychotherapy provided alongside pharm
acological treatm
ent? 
10 (83.3%
) 
49 (86%
) 
.05 
.82 
A
re paraphilic patients m
edically exam
ined before treatm
ent? 
11 (91.7%
) 
56 (98.2%
) 
.08 
.78 
A
re paraphilic patients inform
ed about risks and side effects before pharm
acological 
treatm
ent is com
m
enced? 
12 (100%
) 
53 (93.0%
) 
.01 
1.0 
D
o paraphilic patients have to give w
ritten inform
ed consent before pharm
acological 
treatm
ent is com
m
enced? 
9 (75%
) 
45 (78.9%
) 
.01 
.92 
C
an inform
ed consent be revoked after treatm
ent has com
m
enced?
3 
7 (77.8%
) 
43 (95.6%
) 
1.35 
.25 
W
ould lesser prison sentence or early parole be offered to a paraphilic patient in prison or 
com
parable institution if he agrees to pharm
acological treatm
ent? 
4 (33.3%
) 
21 (36.8%
) 
.01 
.92 
O
nce treatm
ent has started is the patient’s suitability subject to review
? 
12 (100%
) 
52 (91.2%
) 
.2 
.65 
W
ould the patient’s partner or w
ife be involved in the decision about pharm
acological 
treatm
ent? 
5 (41.7%
) 
37 (64.9%
) 
1.38 
.24 
